An action packed day 3 here at #ASH24! 🎥 🗞️🩸🇺🇸 Today we’ve spoken to: 🌟 Sanam Loghavi about all things #AMLsm 🌟 Omar Nadeem MD about exploring innovative therapies for high-risk smoldering myeloma and relapsed/refractory multiple myeloma 🌟 Julio Chavez MD on advances in #lymphoma care 🌟 Issa Khouri who spoke on adding inotuzumab ozogamicin to a melphalan + fludarabine redced-intensity conditioning regimen shows promise for allogeneic transplant in ALL and aggressive lymphoid malignancies 🌟 Shai Shimony on new insights in #AML and #BPDCN care 🌟 Jack Khouri, MD, FACP about an EASIX-based predictive model for ICANS & CRS after CAR-T therapy & Outcomes of teclistamab in pts with RRMM with prior exposure to BCMA-directed therapy 🌟 Enrique M. Ocio who discussed long-term efficacy and safety of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed patients with #MultipleMyeloma patients not eligible for transplant or with no immediate transplant intent 🌟 Marina Konopleva who discussed innovative therapies presented at #ASH24 such as: tagraxofusp which shows promise in BPDCN with rapid hematopoiesis recovery & novel non-transplant options emerging for high-risk TP53 myeloid disease & many more! Stay tuned as we continue to share our exclusive coverage 👀 👉 https://lnkd.in/eBQtCaCs #Hematologynews #HemOnc
-
+2